What You Should Know:
– Q Bio Inc., a pioneer in medical imaging technology secures $27M in strategic funding to propel its innovative Mark I full-body scanner towards market launch. This investment round welcomes new investor TELUS Global Ventures alongside existing backers like Khosla Ventures, Andreessen Horowitz, Founders Fund, and Kaiser Foundation Hospitals.
– Founded in 2015 by Jeff Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, Q Bio is dedicated to revolutionizing medical imaging with innovative technologies like the Mark I scanner.
Mark I: Redefining the Future of Medical Imaging
The Mark I represents a groundbreaking advancement in MRI technology, offering a significant leap forward from traditional methods. Utilizing Q Bio’s proprietary Tensor Field Mapping technology, Mark I delivers full-body scans with immediate access to quantifiable data across a staggering 3,000 anatomical measurements – a first in the field.
Key Advantages of Mark I:
- Comprehensive Data in One Scan: Mark I eliminates the need for multiple scans by capturing extensive quantitative anatomical data in a single session. This data fuels the creation of “digital twins” and large biological models, offering unparalleled insights into human health.
- Patient Comfort at the Forefront: Unlike conventional MRI machines, Mark I boasts an open design, eliminating the requirement for enclosed spaces. Additionally, scans are completed in just 10 minutes and require no breath-holding or radiation exposure, ensuring a more comfortable and accessible experience for patients.
- Versatility for Diverse Settings: Unlike traditional MRI machines with stringent infrastructure needs, Mark I is designed for adaptability. Its compact size and simplified operation make it suitable for deployment in various settings, from primary care clinics to hospital environments.
“The early interest we’re seeing in the Mark I is considerable, and this new funding will bolster our efforts to accelerate manufacturing plans as we continue our journey through regulatory approvals in the United States,” said Clarissa Shen, Chief Operating Officer at Q Bio.
